Page 673 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 40 Thalassemia Syndromes 570.e5

207. Berdoukas V, Chouliaras G, Moraitis P, et al: The efficacy of iron 231. Wanless IR, Sweeney G, Dhillon AP, et al: Lack of progressive hepatic
chelator regimes in reducing cardiac and hepatic iron in patients with fibrosis during long-term therapy with deferiprone in subjects with
thalassaemia major: a clinical observational study. J Cardiovasc Magn transfusion-dependent beta-thalassemia. Blood 100:1566, 2002.
Reson 11:20, 2009. 232. Cragg L, Hebbel RP, Miller W, et al: The iron chelator L1 potentiates
208. Olivieri NF, Brittenham GM, Matsui D, et al: Iron-chelation therapy oxidative DNA damage in iron-loaded liver cells. Blood 92:632, 1998.
with oral deferipronein patients with thalassemia major. N Engl J Med 233. Tanner M, Galanello R, Dessi C, et al: A randomized placebo con-
332:918, 1995. trolled double blind trial of the effect of combination therapy with
209. Olivieri NF, Brittenham GM, McLaren CE, et al: Long-term safety and deferoxamine and deferiprone on myocardial iron in thalassemia major
effectiveness of iron-chelation therapy with deferiprone for thalassemia using cardiovascular magnetic resonance. Blood 106:1017A, 2006.
major. N Engl J Med 339:417, 1998. 234. de Franceschi L, Shalev O, Piga A, et al: Deferiprone therapy in
210. Hoffbrand AV, AL-Refaie F, Davis B, et al: Long-term trial of deferi- homozygous human beta-thalassemia removes erythrocyte membrane
prone in 51 transfusion-dependent iron overloaded patients. Blood free iron and reduces KCl cotransport activity. J Lab Clin Med 133:64,
91:295, 1998. 1999.
211. Hoffbrand AV, Cohen A, Hershko C: Role of deferiprone in chelation 235. Giardina PJ, Grady RW: Chelation therapy in beta-thalassemia: an
therapy for transfusional iron overload. Blood 102:17, 2003. optimistic update. Semin Hematol 38:360, 2001.
212. Cohen AR, Galanello R, Piga A, et al: Safety and effectiveness of long- 236. Pippard MJ, Weatherall DJ: Oral iron chelation therapy for thalassae-
term therapy with the oral iron chelator deferiprone. Blood 102:1583, mia: an uncertain scene. Br J Haematol 111:2, 2000.
2003. 237. Nick H, Acklin P, Lattmann R, et al: Development of tridentate iron
213. Cohen AR, Galanello R, Piga A, et al: Safety profile of the oral iron chelators: from desferrithiocin to ICL670. Curr Med Chem 10:1065,
chelator deferiprone: a multicentre study. Br J Haematol 108:305, 2000. 2003.
214. Ceci A, Baiardi P, Felisi M, et al: The safety and effectiveness of deferi- 238. Piga A, Galanello R, Cappellini M, et al: Phase II study of ICL670,
prone in a large-scale, 3-year study in Italian patients. Br J Haematol an oral chelator, in adult thalassemia patients with transfusional iron
118:330, 2002. overload: efficay, safety pharmacokinetics (PK) and pharmacodymanics
215. Del Vecchio GC, Crollo E, Schettini F, et al: Factors influencing (PD) after 18 months of therapy. Blood 102:121a, 2003.
effectiveness of deferiprone in a thalassaemia major clinical setting. 239. Nisbet-Brown E, Olivieri NF, Giardina PJ, et al: Effectiveness and
Acta Haematol 104:99, 2000. safety of ICL670 in iron-loaded patients with thalassaemia: a ran-
216. Maggio A, D’Amico G, Morabito A, et al: Deferiprone versus deferox- domised, double-blind, placebo-controlled, dose-escalation trial. Lancet
amine in patients with thalassemia major: a randomized clinical trial. 361:1597, 2003.
Blood Cells Mol Dis 28:196, 2002. 240. Cappellini MD, Cohen A, Piga A, et al: A phase 3 study of deferasirox
217. Mazza P, Amurri B, Lazzari G, et al: Oral iron chelating therapy. (ICL670), a once-daily oral iron chelator, in patients with beta-
A single center interim report on deferiprone (L1) in thalassemia. thalassemia. Blood 107:3455, 2006.
Haematologica 83:496, 1998. 241. Cohen AR, Glimm E, Porter JB: Effect of transfusional iron intake on
218. Taher A, Sheikh-Taha M, Sharara A, et al: Safety and effectiveness response to chelation therapy in beta-thalassemia major. Blood 111:583,
of 100 mg/kg/day deferiprone in patients with thalassemia major: a 2008.
two-year study. Acta Haematol 114:146, 2005. 242. Porter J, Galanello R, Saglio G, et al: Relative response of patients with
219. Wonke B, Wright C, Hoffbrand AV: Combined therapy with deferi- myelodysplastic syndromes and other transfusion-dependent anaemias
prone and desferrioxamine. Br J Haematol 103:361, 1998. to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol
220. Mourad FH, Hoffbrand AV, Sheikh-Taha M, et al: Comparison 80:168, 2008.
between desferrioxamine and combined therapy with desferrioxamine 243. Taher A, El-Beshlawy A, Elalfy MS, et al: Efficacy and safety of defera-
and deferiprone in iron overloaded thalassaemia patients. Br J Haematol sirox, an oral iron chelator, in heavily iron-overloaded patients with
121:187, 2003. beta-thalassaemia: the ESCALATOR study. Eur J Haematol 82:458,
221. Kattamis A, Ladis V, Berdousi H, et al: Iron chelation treatment with 2009.
combined therapy with deferiprone and deferioxamine: a 12-month 244. Pennell DJ, Porter JB, Cappellini MD, et al: Continued improvement
trial. Blood Cells Mol Dis 36:21, 2006. in myocardial T2* over two years of deferasirox therapy in beta-
222. Grady RW, et al: Combination of desferrioxamine and deferiprone thalassemia major patients with cardiac iron overload. Haematologica
markedly enhances iron excretion. Blood 100:241, 2002. 96:48, 2011.
223. Piga A, Gaglioti C, Fogliacco E, et al: Comparative effects of deferi- 245. Cassinerio E, Roghi A, Orofino N, et al: A 5-year follow-up in defera-
prone and deferoxamine on survival and cardiac disease in patients sirox treatment: improvement of cardiac and hepatic iron overload and
with thalassemia major: a retrospective analysis. Haematologica 88:489, amelioration in cardiac function in thalassemia major patients. Ann
2003. Hematol 94(6):939–945, 2015.
224. Borgna-Pignatti C, Cappellini MD, De Stefano P, et al: Cardiac mor- 246. Pennell DJ, Porter JB, Piga A, et al; CORDELIA study investigators:
bidity and mortality in deferoxamine- or deferiprone-treated patients Sustained improvements in myocardial T2* over 2 years in severely
with thalassemia major. Blood 107:3733, 2006. iron-overloaded patients with beta thalassemia major treated with
225. Aydinok Y, Nisli G, Kavakli K: Alternate use of deferiprone and desfer- deferasirox or deferoxamine. Am J Hematol 90(2):91–96, 2015.
rioxamine in primary school children with thalassaemia major. Br J 247. Wood JC, Kang BP, Thompson A, et al: The effect of deferasirox on
Haematol 106:252, 1999. cardiac iron in thalassemia major: impact of total body iron stores. Blood
226. Pennell DJ, Berdoukas V, Karagiorga M, et al: Randomized controlled 116:537, 2010.
trial of deferiprone or deferoxamine in beta-thalassemia major patients 248. Pennell DJ, Porter JB, Cappellini MD, et al: Efficacy of deferasirox
with asymptomatic myocardial siderosis. Blood 107:3738, 2006. in reducing and preventing cardiac iron overload in beta-thalassemia.
227. Farmaki K, Tzoumari I, Pappa C, et al: Normalisation of total body Blood 115:2364, 2010.
iron load with very intensive combined chelation reverses cardiac and 249. Elalfy MS, Adly AM, Wali Y, et al: Efficacy and safety of a novel combi-
endocrine complications of thalassaemia major. Br J Haematol 148:466, nation of two oral chelators deferasirox/deferiprone over deferoxamine/
2010. deferiprone in severely iron overloaded young beta thalassemia major
228. Piga A, Roggero S, Vinciguerra T, et al: Deferiprone: New insight. Ann patients. Eur J Haematol 95:411–420, 2015.
N Y Acad Sci 1054:169, 2005. 250. Piga A, Fracchia S, Lai ME, et al: Deferasirox effect on renal hae-
229. El-Beshlawy AM, El-Alfy MS, Sari TT, et al: Continuation of deferi- modynamic parameters in patients with transfusion-dependent β
prone therapy in patients with mild neutropenia may not lead to a more thalassaemia. Br J Haematol 168(6):882–890, 2015.
severe drop in neutrophil count. Eur J Haematol 92(4):337–340, 2014. 251. Cunningham MJ, Macklin EA, Neufeld EJ, et al: Complications
230. Kowdley KV, Kaplan MM: Iron-chelation therapy with oral of beta-thalassemia major in North America. Blood 104(1):34–39,
deferiprone–toxicity or lack of efficacy? N Engl J Med 339:468, 1998. 2004.